Waldenström’s macroglobulinemia – clinical symptoms and review of therapy yesterday, today and tomorrow
Authors:
Z. Adam 1; L. Pour 1; D. Zeman 2; M. Krejčí 1; I. Boichuk 1; M. Krejčí 1; M. Štork 1; V. Sandecká 1; Z. Král 1
Authors‘ workplace:
Interní hematologická a onkologická klinika LF MU a FN Brno
1; Oddělení klinické bio chemie, Ústav laboratorní medicíny LF MU a FN Brno
2
Published in:
Klin Onkol 2023; 36(3): 177-191
Category:
Review
doi:
https://doi.org/10.48095/ccko2023177
Overview
Background: Waldenström macroglobulinemia (WM) is a lymphoplasmocytic lymphoma with immunoglobulin M monoclonal protein. The incidence of this disease is very low (0.4/100,000), so that this disease can be regarded as an orphan’s disease. It means that new drugs are often tested and registered for more frequent diseases. Purpose: In this review we will focus on the efficacy of the new drugs for WM. Results: The current treatment options for symptomatic WM patients include alkylating agent cyclophosphamide and anti-CD20 monoclonal antibodies. Therapy with rituximab and bendamustin resulted in longer therapeutic response then therapy with rituximab, cyclophosphamide and dexamethasone. Many drugs, used in multiple myeloma (MM), shoved promising results in WM patients. Bortezomib is effective in WM, but its neurotoxicity is higher in WM than in MM patients. Therefore, new proteasome inhibitors, carfilzomib and ixazomib, are better tolerated as documented in several studies. New types of antiCD20 antibody (obinutuzumab) can be used in patients with rituximab intolerance. in five of our patients with WM, obinutuzumab and bendamustin reached deeper responses than therapies administered in previous lines of therapy. Oral Bruton tyrosine kinase (BTK) inhibitor ibrutinib alone and in combination with rituximab have extended the treatment options for WM patients. New BTK inhibitors (e. g. acalabrutinib, zanubrutinib, and vecabrutinib) were tested and their lower toxicity (atrial fibrillation) was documented. Moreover, the BCL2 inhibitor venetoclax is newly tested. Conclusion: New antiCD20 antibody (obinutuzumab) is of advantage in patients with WM with rituximab intolerance as well as bendamustin and new proteasome inhibitors (ixazomib and carfilzomib) or new BTK inhibitors with lower cardiotoxicity. Many of the abovementioned drugs do not have official registration for WM and can be administrated with the consent of the health care provider only. Thus, this work brings evidence of their efficacy.
Keywords:
ibrutinib – obinutuzumab – Waldenström macroglobulinemia – ixazomib – bendamustin – carfilzomib
Sources
1. Ščudla V, Minařík J, Pika T et al. Diferenciální diagnostika monoklonálních gamapatií z pohledu klinické praxe. I. maligní monoklonální gamapatie. Int Med Praxi 2017; 19 (5): 274–278. doi: 10.36290/int.2017.060.
2. Kyle RA, Larson DR, Therneau TM et al. Long-term follow-up of monoclonal gammopathy of undetermined significance. N Engl J Med 2018; 378 (3): 241–249. doi: 10.1056/NEJMoa1709974.
3. Varettoni M, Zibellini S, Boveri E et al. A risk-stratification model based on the initial concentration of the serum monoclonal protein and MYD88 mutation status identifies a subset of patients with IgM monoclonal gammopathy of undetermined significance at high risk of progression to Waldenstrom macroglobulinaemia or other lymphoproliferative disorders. Br J Haematol 2019; 187 (4): 441–446. doi: 10.1111/bjh.16086.
4. Sandecká V, Adam Z, Krejčí M et al. Diagnostic relevance of 18F-FDG PET/CT in newly diagnosed patients with monoclonal gammopathy of undetermined significance (MGUS): Single-center experience. Neoplasma 2020; 67 (4): 939–945. doi: 10.4149/neo_2020_191104N1137.
5. Wang H, Chen Y, Li F et al. Temporal and geographic variations of Waldenstrom macroglobulinemia incidence: a large population-based study. Cancer 2012; 118 (15): 3793–3800. doi: 10.1002/cncr.26627.
6. Castillo JJ, Olszewski AJ, Kanan S et al. Overall survival and competing risks of death in patients with Waldenström macroglobulinaemia: an analysis of the Surveillance, Epidemiology and End Results database. Br J Haematol 2015; 169 (1): 81–89. doi: 10.1111/bjh.13264.
7. Nanah A, Al Hadidi S. Bing-Neel syndrome: update on the diagnosis and treatment. Clin Lymphoma Myeloma Leuk 2022; 22 (3): e213–e219. doi: 10.1016/j.clml.2021.09.014.
8. Pika T, Kosatíková Z, Juráňová J et al. Nekorpuskulární hyperviskózní syndromy v klinické praxi. Int Med Praxi 2014; 16 (4): 156–158.
9. Jonsson V, Kierkegaard A, Salling S et al. Autoimunity in Waldenström’s macroglobulinemia. Leuk Lymphoma 1999; 34 (3–4): 373–379. doi: 10.3109/10428199909050962.
10. Pika T, Flodr P, Novák M et al. Klinická problematika IgM noklonálních gamapatií. Klin Biochem Metab 2014; 22 (2): 61–64.
11. Owen RG, Treon SP, Al-Katib A et al. Clinicopathological definition of Waldenstrom’s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia. Semin Oncol 2003; 30 (2): 110–115. doi: 10.1053/sonc.2003.50082.
12. Gerz MA. Waldenström macroglobulinemia: 2021 update on diagnosis, risk stratification, and management. Am J Hematol 2021; 96 (2): 258–269. doi: 10.1002/ajh.26 082.
13. Gavriatopoulou M, Musto P, Caers J et al. European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. Leukemia 2018; 32 (9): 1883–1898. doi: 10.1038/s41375-018-0209-7.
14. Elba S, Castellino A, Soriasio R et al. Immunoglobulin M (IgM) multiple myeloma versus Waldenström macroglobulinemia: diagnostic challenges and therapeutic options: two case reports. J Med Case Rep 2020; 14 (1): 75. doi: 10.1186/s13256-020-02380-2.
15. Jelínek T, Bezděkova R, Zátopková M et al. Current applications of multiparameter flow cytometry in plasma cell disorders. Blood Cancer J 2017; 7 (10): e617. doi: 10.1038/bcj.2017.90.
16. Baďurová K, Gregorová J, Vlachová M et al. Waldenström macroglobulinemia. Klin Onkol 2021; 34 (6): 428–433. doi: 10.48095/ccko2021428.
17. Sedlaříková L, Sadílková K, Bešše L et al. Cytokine profiles of multiple myeloma and Waldenström macroglobulinemia. Klin Onkol 2014; 27 (1): 18–23. doi: 10.14735/amko201418.
18. Banwait R, O’Regan K, Campigotto F et al. The role of 18F-FDG PET/CT imaging in Waldenstrom macroglobulinemia. Am J Hematol 2011; 86 (7): 567–572. doi: 10.1002/ajh.22044.
19. Kaščák M, Hájek R, Minařík J et al. Diagnostika a léčba Waldenströmovy makroglobulinémie. Trans Hematol Dnes 2022; 28 (Suppl 1): S44–S74. doi: 10.48095/cctahd2022S42.
20. Leleu X, Xie W, Bagshaw M et al. The role of serum immunoglobulin free light chain in response and progression in waldenstrom macroglobulinemia. Clin Cancer Res 2011; 17 (9): 3013–3018. doi: 10.1158/1078-0432.CCR-10-2954.
21. Castillo JJ, Advani RH, Branagan AR et al. Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia. Lancet Haematol 2020; 7 (11): e827–e837. doi: 10.1016/S2352-3026 (20) 30224-6.
22. Kyle RA, Greipp PR, Gertz MA et al. Waldenstrom‘s macroglobulinaemia: a prospective study comparing daily with intermittent oral chlorambucil. Br J Haematol 2000; 108 (4): 737–742. doi: 10.1046/j.1365-2141.2000.01 918.x.
23. Souchet L, Levy V, Ouzegdouh M et al. Efficacy and long-term toxicity of the rituximab-fludarabine-cyclophosphamide combination therapy in Waldenstrom‘s macroglobulinemia. Am J Hematol 2016; 91 (8): 782–786. doi: 10.1002/ajh.24405.
24. Santos-Lozano A, Morales-Gonzalez A, Sanchis-Gomar F et al. Response rate to the treatment of Waldenstrom macroglobulinemia: a meta-analysis of the results of clinical trials. Crit Rev Oncol Hematol 2016; 105: 118–126. doi: 10.1016/j.critrevonc.2016.06.004.
25. Lunn MP. Neuropathies and paraproteins. Curr Opin Neurol 2019; 32 (5): 658–665. doi: 10.1097/WCO.0000 000000000726.
26. Ghobrial IM, Fonseca R, Greipp PR et al. Initial immunoglobulin M ‚flare‘ after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study. Cancer 2004; 101 (11): 2593–2598. doi: 10.1002/cncr.20658.
27. Rummel MJ, Lerchenmüller C, Hensel M et al. Two years rituximab maintenance vs. observation after first line treatment with Bendamustine Plus Rituximab (B-R) in patients with Waldenström‘s Macroglobulinemia (MW): results of a prospective, randomized, multicenter phase 3 study. Blood 2019; 134 (Suppl 1): 343. doi: 10.1182/blood-2019-121909.
28. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC et al. Primary treatment of Waldenstrom macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol 2007; 25 (22): 3344–3349. doi: 10.1200/JCO.2007.10.9926.
29. Kastritis E, Gavriatopoulou M, Kyrtsonis MC et al. Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenstrom macroglobulinemia: final analysis of a phase 2 study. Blood 2015; 126 (11): 1392–1394. doi: 10.1182/blood-2015-05-647420.
30. Mössner E, Brünker P, Moser P et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell mediated B cell cytotoxicity. Blood 2010; 115 (22): 4393–4402. doi: 10.1182/blood-2009-06-225979.
31. Leblond V, Kastritis E, Advani R et al. Treatment recommendations from the Eighth International Workshop on Waldenström‘s Macroglobulinemia. Blood 2016; 128 (10): 1321–1328. doi: 10.1182/blood-2016-04-711234.
32. Gavriatopoulou M, Kastritis E, Kyrtsonis MC et al. Phase 2 study of ofatumumab, fludarabine and cyclophosphamide in relapsed/refraktory Waldenström‘s macroglobulinemia. Leuk Lymphoma 2017; 58 (6): 1506–1508. doi: 10.1080/10428194.2016.1233541.
33. Furman RR, Eradat HA, DiRienzo CG et al. Once-weekly ofatumumab in untreated or relapsed Waldenström‘s macroglobulinaemia: an open-label, single-arm, phase 2 study. Lancet Haematol 2017; 4 (1): e24–e34. doi: 10.1016/S2352-3026 (16) 30166-1.
34. Sehn LH, Chua N, Mayer J et al. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol 2016; 17 (8): 1081–1093. doi: 10.1016/S1470-2045 (16) 30097-3.
35. García-Muñoz R, López-Díaz-de-Cerio A, Feliu J et al. Follicular lymphoma: in vitro effects of combining lymphokine-activated killer (LAK) cell-induced cytotoxicity and rituximab- and obinutuzumab-dependent cellular cytotoxicity (ADCC) activity. Immunol Res 2016; 64 (2): 548–557. doi: 10.1007/s12026-015-8747-9.
36. Herter S, Herting F, Mundigl O et al. Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol Cancer Ther 2013; 12 (10): 2031–2042. doi: 10.1158/1535-7163.MCT-12-1182.
37. Sehn LH, Goy A, Offner FC et al. Randomized phase II trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20+ indolent B cell non-Hodgkin lymphoma: final analysis of the GAUSS study. J Clin Oncol 2015; 33 (30): 3467–3474. doi: 10.1200/JCO.2014.59.2139.
38. Marcus RE, Davies AJ, Ando K et al. Obinutuzumab-based induction and maintenance prolongs progression-free survival (PFS) in patients with previously untreated follicular lymphoma: primary results of the randomized phase 3 GALLIUM study. Blood 2016; 128: 6.
39. Hiddemann W, Barbui AM, Canales MA et al. Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study: influence of chemotherapy on efficacy and safety. J Clin Oncol 2018; 36 (23): 2395–2404. doi: 10.1200/JCO.2017.76.8960.
40. Seymour JF, Marcus R, Davies A et al. Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression. Haematologica 2019; 104 (6): 1202–1208. doi: 10.3324/haematol.2018.209015.
41. Jamois C, Gibiansky E, Gibiansky L et al. Role of obinutuzumab exposure on clinical outcome of follicular lymphoma treated with first-line immunochemotherapy. Br J Clin Pharmacol 2019; 85 (7): 1495–1506. doi: 10.1111/bcp.13920.
42. Salles GA, Morschhauser F, Solal-Céligny P et al. Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the Phase II GAUGUIN study. J Clin Oncol 2013; 31 (23): 2920–2926. doi: 10.1200/JCO.2012.46.9718.
43. Cheson BD, Chua N, Mayer J et al. Overall survival benefit in patients with rituximab-refractory indolent non--Hodgkin lymphoma who received obinutuzumab plus bendamustine induction and obinutuzumab maintenance in the GADOLIN study. J Clin Oncol 2018; 36 (22): 2259–2266. doi: 10.1200/JCO.2017.76.3656.
44. Marcus R, Devies A, Ando K et al. Obinutuzumab for the first-line treatment of Follicular lymphoma. N Eng J Med 2017; 377 (14): 1331–1344. doi: 10.1056/NEJMoa1614598.
45. Goede V, Fischer K, Engelke A et al. Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study. Leukemia 2015; 29 (7): 1602–1604. doi: 10.1038/leu.2015.14.
46. Vitolo U, Trněný M, Belada D et al. Obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-cell lymphoma: final results from an open-label, randomized phase 3 study (GOYA). Blood 2016; 128 (22): 470. doi: 10.1182/blood.V128.22.470.470.
47. Sehn LH, Martelli M, Trněný M et al. A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA. J Hematol Oncol 2020; 13 (1): 71. doi: 10.1186/s13045-020-00900-7.
48. Casasnovas RO, Salles GA, Oberic L et al. Obinutuzumab versus rituximab in combination with ACVBP-14 or CHOP-14 following a PET-driven strategy in Aa-IPI 1–3 DLBCL patients (< 60 years): third planned interim and final analyses of the gained trial. Blood 2017; 130 (Suppl 1): 190. doi: 10.1182/blood.V130.Suppl_1.190.190.
49. Herold M, Hoster E, Janssens A et al. Immunochemotherapy and maintenance with obinutuzumab or rituximab in patients with previously untreated marginal zone lymphoma in the randomized GALLIUM trial. Hemasphere 2022; 6 (3): e699. doi: 10.1097/HS9.0000000000000699.
50. Luo C, Wu G, Huang X et al. Efficacy and safety of new anti-CD20 monoclonal antibodies versus rituximab for induction therapy of CD20+ B-cell non-Hodgkin lymphomas: a systematic review and meta-analysis. Sci Rep 2021; 11 (1): 3255. doi: 10.1038/s41598-021-82841-w.
51. Guzauskas GF, Masaquel A, Thuresson PO et al. Obinutuzumab plus chemotherapy followed by obinutuzumab monotherapy is cost-effective vs. rituximab plus chemotherapy followed by rituximab monotherapy for previously untreated follicular lymphoma patients in the United States. Leuk Lymphoma 2019; 60 (7): 1668–1676. doi: 10.1080/10428194.2018.1551532.
52. Adam Z, Krejčí M, Pour L et al. Obinutuzumab v léčbě pacientky s Waldenströmovou makroglobulinémií netolerující rituximab – popis případu. Transfuze Hematol Dnes 2021; 27 (2): 160–165. doi: 10.48095/cctahd2021160.
53. Tomowiak C, Poulain S, Herbaux C et al. Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenström macroglobulinemia. Blood Adv 2021; 5 (9): 2438–2446. doi: 10.1182/bloodadvances.2020003895.
54. Freeman CL, Sehn LH. A tale of two antibodies: obinutuzumab versus rituximab. Br J Haematol 2018; 182 (1): 29–45. doi: 10.1111/bjh.15232.
55. Treon SP, Hanzis C, Tripsas C et al. Bendamustine therapy in patients with relapsed or refractory Waldenstrom‘s macroglobulinemia. Clin Lymphoma Myeloma Leuk 2011; 11 (1): 133–135. doi: 10.3816/CLML.2011.n.030.
56. Tedeschi A, Picardi P, Ferrero S et al. Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenstrom macroglobulinemia. Leuk Lymphoma 2015; 56 (9): 2637–2642. doi: 10.3109/10428194.2015.1012714.
57. Laribi K, Poulain S, Willems L et al. Bendamustine plus rituximab in newly-diagnosed Waldenstrom macroglobulinaemia patients. A study on behalf of the French Innovative Leukaemia Organization (FILO). Br J Haematol 2019; 186 (1): 146–149. doi: 10.1111/bjh.15718.
58. Rummel MJ, Lerchenmüller C, Hensel M et al. Two years rituximab maintenance vs. observation after first line treatment with Bendamustine Plus Rituximab (B-R) in patients with Waldenström‘s Macroglobulinemia (MW): results of a prospective, randomized, multicenter phase 3 study (the StiL NHL7-2008 MAINTAIN trial). Blood 2019; 134 (8): 343.
59. Rummel MJ, Niederle N, Maschmeyer G et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013; 381 (9873): 1203–1210. doi: 10.1016/S0140-6736 (12) 61763-2.
60. Castillo JJ, Gustine J, Meid K et al. Bendamustine and bortezomib-containing regimens produce higher response rates and more durable responses versus cyclophosphamide-based therapy in frontline Waldenstrom macroglobulinemia. Blood 2017; 130 (Suppl 1): 1488–1489.
61. Paludo J, Abeykoon JP, Shreders A et al. Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenstrom macroglobulinemia. Ann Hematol 2018; 97 (8): 1417–1425. doi: 10.1007/s00277-018-3311-z.
62. Santos-Lozano A, Morales-Gonzalez A, Sanchis-Gomar F et al. Response rate to the treatment of Waldenström macroglobulinemia: a meta-analysis of the results of clinical trials. Crit Rev Oncol Hematol 2016; 105: 118–126. doi: 10.1016/j.critrevonc.2016.06.004.
63. Castillo JJ, Itchaki G, Paludo J et al. Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study. Blood 2019; 133 (4): 299–305. doi: 10.1182/blood-2018-10-879593.
64. Benevolo G, Ferrero S, Villivà N et al. Treatment of relapsed/refractory Waldenström macroglobulinemia patients: final clinical and molecular results of the phase II Brb (Bendamustine, Rituximab and Bortezomib) trial of the Fondazione Italiana Linfomi (FIL). Blood 2021; 138 (Suppl 1): 48. doi: 10.1182/blood-2021-148424.
65. Chan WLW, Chong VCL, Wee IJY et al. Evaluating front line treatment regimens for Waldenstrom macroglobulinaemia: a systematic review and meta-analysis. Blood 2021; 138 (Suppl 1): 1358. doi: 10.1182/blood-2021-150678.
66. Treon SP, Soumerai JD, Branagan AR et al. Thalidomide and rituximab in Waldenstrom macroglobulinemia. Blood 2008; 112 (12): 4452–4457. doi: 10.1182/blood-2008-04-150854.
67. Treon SP, Soumerai JD, Branagan AR et al. Lenalidomide and rituximab in Waldenstrom‘s macroglobulinemia. Clin Cancer Res 2009; 15 (1): 355–360. doi: 10.1158/1078-0432.CCR-08-0862.
68. Fouquet G, Guidez S, Petillon MO et al. Lenalidomide is safe and active in Waldenström macroglobulinemia. Am J Hematol 2015; 90 (11): 1055–1059. doi: 10.1002/ajh.24175.
69. Dimopoulos MA, Chen C, Kastritis E et al. Bortezomib as a treatment option in patients with Waldenstrom macroglobulinemia. Clin Lymphoma Myeloma Leuk 2010; 10 (2): 110–117. doi: 10.3816/CLML.2010.n.015.
70. Dimopoulos MA, Terpos E, Kastritis E. Proteasome inhibitor therapy for Waldenström‘s macroglobulinemia. Clin Lymphoma Myeloma Leuk 2013; 13 (2): 235–237. doi: 10.1016/j.clml.2013.02.014.
71. Treon SP, Ioakimidis L, Soumerai JD et al. Primary therapy of Waldenstrom macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. J Clin Oncol 2009; 27 (23): 3830–3835. doi: 10.1200/JCO.2008.20.4677.
72. Chen C, Kouroukis CT, White D et al. Bortezomib in relapsed or refractory Waldenstrom‘s macroglobulinemia. Clin Lymphoma Myeloma 2009; 9 (1): 74–76. doi: 10.3816/CLM.2009.n.019.
73. Ghobrial IM, Xie W, Padmanabhan S et al. Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenstrom macroglobulinemia. Am J Hematol 2010; 85 (9): 670–674. doi: 10.1002/ajh.21788.
74. Sklavenitis-Pistofidis R, Capelletti M, Liu CJ et al. Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients. Blood 2018; 132 (24): 2608–2612. doi: 10.1182/blood-2018-07-863241.
75. Gavriatopoulou M, Garcia-Sanz R, Kastritis E et al. BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years. Blood 2017; 129 (4): 456–459. doi: 10.1182/blood-2016-09-742411.
76. Dimopoulos MA, Garcia-Sanz R, Gavriatopoulou M et al. Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-termresults of a phase 2 study of the European Myeloma Network (EMN). Blood 2013; 122 (19): 3276–3782. doi: 10.1182/blood-2013-05-503862.
77. Rossi G, Gramegna D, Paoloni F et al. Short course of bortezomib in anemic patients with relapsed cold agglutinin disease: a phase 2 prospective GIMEMA study. Blood 2018; 132 (5): 547–550. doi: 10.1182/blood-2018-03-835413.
78. Berentsen S, Barcellini W, D’Sa S et al. Cold agglutinin disease revisited: a multinational observational study of 232 pacients. Blood 2022; 136 (4): 480–488. doi: 10.1182/blood.2020005674.
79. Kong D, Li Y, Fu C et al. Bortezomib provides favorable efficacy in type 3 acquired von willebrand syndrome related to lymphoplasmacytic lymphoma/Waldenstrom‘s macroglobulinemia. Leuk Lymphoma 2022; 63 (2): 491–494. doi: 10.1080/10428194.2021.1992766.
80. Ojeda-Uribe M, Rimelen V, Marzullo C. Good profile of efficacy/tolerance of bortezomib or idelalisib in Waldenström macroglobulinemia associated with acquired Von Willebrand syndrome. J Blood Med 2020; 11: 67–72. doi: 10.2147/JBM.S233059.
81. Treon SP, Tripsas CK, Meid K et al. Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström‘s macroglobulinemia. Blood 2014; 124 (4): 503–510. doi: 10.1182/blood-2014-03-566273.
82. Vesole DH, Richter J, Biran N et al. Carfilzomib as salvage therapy in Waldenstrom macroglobulinemia: a case series. Leuk Lymphoma 2018; 59 (1): 259–261. doi: 10.1080/10428194.2017.1321749.
83. Chaudhry M, Steiner R, Claussen C et al. Carfilzomib-based combination regimens are highly effective frontline therapies for multiple myeloma and Waldenstrom‘s macroglobulinemia. Leuk Lymphoma 2019; 60 (4): 964–970. doi: 10.1080/10428194.2018.1508668.
84. Castillo JJ, Meid K, Catherine A et al. Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenström macroglobulinemia: long-term follow--up. Blood Adv 2020; 4 (16): 3952–3959. doi: 10.1182/bloodadvances.2020001963.
85. Kersten MJ, Amaador K, Minnema MC et al. Combining ixazomib with subcutaneous rituximab and dexamethasone in relapsed or refractory Waldenström’s macroglobulinemia: final analysis of the phase I/II HOVON124/ECWM-R2 study. J Clin Oncol 2022; 40 (1): 40–51. doi: 10.1200/JCO.21.00105.
86. Kastritis E, Dimopoulos MA. Proteasome inhibitors in Waldenström macroglobulinemia. Hematol Oncol Clin North Am 2018; 32 (5): 829–840. doi: 10.1016/j.hoc.2018.05.011.
87. Fečková-Mihályová J, Ďuraš J, Zuchnická J et al. Ibrutinib v hematoonkologii. Klin Farmakol Farm 2016; 30 (3): 8–14. doi: 10.36290/far.2016.022.
88. Treon SP, Tripsas CK, Meid K et al. Ibrutinib in previously treated Waldenstrom‘s macroglobulinemia. N Engl J Med 2015; 372 (15): 1430–1440. doi: 10.1056/NEJMoa1501548.
89. Yun S, Vincelette ND, Acharya U et al. Risk of atrial fibrillation and bleeding diathesis associated with Ibrutinib treatment: a systematic review and pooled analysis of four randomized controlled trials. Clin Lymphoma Myeloma Leuk 2017; 17 (1): 31–37. doi: 10.1016/j.clml.2016.09.010.
90. Gustine JN, Meid K, Dubeau T et al. Ibrutinib discontinuation in Waldenstrom macroglobulinemia: etiologies, outcomes, and IgM rebound. Am J Hematol 2018; 93 (4): 511–517. doi: 10.1002/ajh.25023.
91. Treon SP, Xu L, Hunter Z. MYD88 mutations and response to ibrutinib in Waldenstrom’s macroglobulinemia. N Engl J Med 2015; 373 (6): 584–586. doi: 10.1056/NEJMc1506192.
92. Dimopoulos MA, Trotman J, Tedeschi A et al. Ibrutinib for patients with rituximab-refractory Waldenstrom‘s macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. Lancet Oncol 2017; 18 (2): 241–250. doi: 10.1016/S1470-2045 (16) 30632-5.
93. Treon SP, Gustine J, Meid K et al. Ibrutinib is highly active as first line therapy in symptomatic Waldenstrom‘s macroglobulinemia. Blood 2017; 130 (Suppl 1): 2767. doi: 10.1182/BLOOD.V130.SUPPL_1.2767.2767.
94. Treon SP, Gustine J, Meid K et al. Ibrutinib monotherapy in symptomatic, treatment-naive patients with Waldenstrom macroglobulinemia. J Clin Oncol 2018; 36 (27): 2755–2761. doi: 10.1200/JCO.2018.78.6426.
95. Abeykoon JP, Zanwar S, Ansell SM et al. Ibrutinib monotherapy outside of clinical trial setting in Waldenstrom macroglobulinaemia: practice patterns, toxicities and outcomes. Br J Haematol 2020; 188 (3): 394–403. doi: 10.1111/bjh.16168.
96. Buske C, Tedeschi A, Trotman J et al. Ibrutinib plus rituximab versus placebo plus rituximab for Waldenström’s macroglobulinemia: final analysis from the randomized phase III iNNOVATE study. J Clin Oncol 2022; 40 (1): 52–62. doi: 10.1200/JCO.21.00838.
97. Castillo JJ, Gustine JN, Meid K et al. Impact of ibrutinib dose intensity on patient outcomes in previously treated Waldenstrom macroglobulinemia. Haematologica 2018; 103 (10): e466–e468. doi: 10.3324/haematol.2018.191 999.
98. Castillo JJ, Gustine JN, Meid K et al. Ibrutinib withdrawal symptoms in patients with Waldenström macroglobulinemia. Haematologica 2018; 103 (7): e307–e310. doi: 10.3324/haematol.2017.186908.
99. Paydas S. Management of adverse effects/toxicity of ibrutinib. Crit Rev Oncol Hematol 2019; 136: 56–63. doi: 10.1016/j.critrevonc.2019.02.001.
100. Abbas HA, Wierda WG. Acalabrutinib: a selective bruton tyrosine kinase inhibitor for the treatment of B-cell malignancies. Front Oncol 2021; 11: 668162. doi: 10.3389/fonc.2021.668162.
101. Owen RG, McCarthy H, Rule S et al. Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study. Lancet Haematol 2020; 7 (2): e112–e121. doi: 10.1016/S2352-3026 (19) 30210-8.
102. Tam CS, Opat S, D’Sa S et al. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study. Blood 2020; 136 (18): 2038–2050. doi: 10.1182/blood.2020006844.
103. Tam CS, LeBlond V, Novotny W et al. A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia. Future Oncol 2018; 14 (22): 2229–2237. doi: 10.2217/fon-2018-0163.
104. Dimopoulos M, Sanz RG, Lee HP et al. Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial. Blood Adv 2020; 4 (23): 6009–6018. doi: 10.1182/bloodadvances.2020003010.
105. Argyropoulos KV, Palomba ML. First-generation and second-generation bruton tyrosine kinase inhibitors in Waldenström macroglobulinemia. Hematol Oncol Clin North Am 2018; 32 (5): 853–864. doi: 10.1016/j.hoc.2018.05.012.
106. Munakata W, Tobinai K. Tirabrutinib hydrochloride for B-cell lymphomas. Drugs Today (Barc) 2021; 57 (4): 277–289. doi: 10.1358/dot.2021.57.4.3264113.
107. Castillo JJ, Allan JN, Siddiqi T et al. Venetoclax in previously treated Waldenström macroglobulinemia. J Clin Oncol 2022; 40 (1): 63–71. doi: 10.1200/JCO.21.01194.
108. Novák J, Havrda M, Gahérová Ľ et al. Clinical case: idelalisib-induced immunoglobulin flare. Immunopharmacol Immunotoxicol 2017; 39 (4): 251–255. doi: 10.1080/08923973.2017.1318912.
109. Belada D. Idelalisib v léčbě pacientů s folikulárním lymfomem. Farmakoterapie 2015; 11 (3): 292–296.
110. Kyriakou C. High-dose therapy and hematopoietic stem cell transplantation in Waldenström macroglobulinemia. Hematol Oncol Clin North Am 2018; 32 (5): 865–874. doi: 10.1016/j.hoc.2018.05.013.
111. Kaščák M, Ďuraš J, Navrátil M et al. Autologní transplantace kmenových buněk u Waldenströmovy makroglobulinemie. Transfuze Hematol Dnes 2016; 22 (1): 28–38.
Labels
Paediatric clinical oncology Surgery Clinical oncologyArticle was published in
Clinical Oncology
2023 Issue 3
Most read in this issue
- Waldenström’s macroglobulinemia – clinical symptoms and review of therapy yesterday, today and tomorrow
- Molecular testing of endometrial carcinoma in real-world clinical practice
- Polygenic risk score (PRS) and its potential for breast cancer risk stratification
- Hypoplastic form of myelodysplastic neoplasm